At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 5, 2026 at 07:03 ET
Invivyd reported strong Q4 and full-year 2025 financial results with PEMGARDA net product revenue of $17.2 million (up 25% YoY) and full-year revenue of $53.4 million (up 110% YoY), while significantly reducing R&D expenses to $38.3 million from $137.3 million. The company ended 2025 with $226.7 million in cash after raising over $200 million, supporting its pivotal DECLARATION Phase 3 trial for VYD2311 with top-line data expected mid-2026.
- Q4 2025 PEMGARDA net revenue: $17.2M, up 25% YoY and 31% QoQ
- Full-year 2025 PEMGARDA net revenue: $53.4M, up 110% from $25.4M in 2024
- R&D expenses dropped to $38.3M in 2025 from $137.3M in 2024
- Cash and cash equivalents: $226.7M as of Dec 31, 2025, after raising over $200M in 2H 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access